**No vaccine is positioned for approval or availability by the end of 2026.** All candidates remain in preclinical or early Phase 1 stages, with no ongoing Phase 3 efficacy trials and substantial regulatory and manufacturing hurdles ahead. mRNA efforts, such as the Moderna–Korea University collaboration, have shown protective effects in rodent models but require further optimization, GMP manufacturing, and human testing projected into 2028 or later. DNA vaccine candidates against Andes virus completed small Phase 1 studies demonstrating immunogenicity yet need additional dosing regimens and larger trials. The low incidence of hantavirus pulmonary syndrome and geographic dispersion of cases complicate large-scale efficacy testing, while the absence of established surrogate endpoints limits accelerated pathways. A sudden large-scale outbreak could prompt emergency-use considerations, but completing required safety, immunogenicity, and manufacturing milestones within the remaining months of 2026 remains highly improbable.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
3% khả năng
$138,610 KL.
$138,610 KL.
Dec 31, 2026
3% khả năng
$138,610 KL.
$138,610 KL.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No vaccine is positioned for approval or availability by the end of 2026.** All candidates remain in preclinical or early Phase 1 stages, with no ongoing Phase 3 efficacy trials and substantial regulatory and manufacturing hurdles ahead. mRNA efforts, such as the Moderna–Korea University collaboration, have shown protective effects in rodent models but require further optimization, GMP manufacturing, and human testing projected into 2028 or later. DNA vaccine candidates against Andes virus completed small Phase 1 studies demonstrating immunogenicity yet need additional dosing regimens and larger trials. The low incidence of hantavirus pulmonary syndrome and geographic dispersion of cases complicate large-scale efficacy testing, while the absence of established surrogate endpoints limits accelerated pathways. A sudden large-scale outbreak could prompt emergency-use considerations, but completing required safety, immunogenicity, and manufacturing milestones within the remaining months of 2026 remains highly improbable.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Thị trường mở: May 4, 2026, 10:39 AM ET
Khối lượng
$138,610Ngày kết thúc
Jan 1, 2027Thị trường mở
May 4, 2026, 10:39 AM ETNgười giải quyết
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No vaccine is positioned for approval or availability by the end of 2026.** All candidates remain in preclinical or early Phase 1 stages, with no ongoing Phase 3 efficacy trials and substantial regulatory and manufacturing hurdles ahead. mRNA efforts, such as the Moderna–Korea University collaboration, have shown protective effects in rodent models but require further optimization, GMP manufacturing, and human testing projected into 2028 or later. DNA vaccine candidates against Andes virus completed small Phase 1 studies demonstrating immunogenicity yet need additional dosing regimens and larger trials. The low incidence of hantavirus pulmonary syndrome and geographic dispersion of cases complicate large-scale efficacy testing, while the absence of established surrogate endpoints limits accelerated pathways. A sudden large-scale outbreak could prompt emergency-use considerations, but completing required safety, immunogenicity, and manufacturing milestones within the remaining months of 2026 remains highly improbable.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Khối lượng
$138,610Ngày kết thúc
Jan 1, 2027Thị trường mở
May 4, 2026, 10:39 AM ETNgười giải quyết
0x65070BE91...**No vaccine is positioned for approval or availability by the end of 2026.** All candidates remain in preclinical or early Phase 1 stages, with no ongoing Phase 3 efficacy trials and substantial regulatory and manufacturing hurdles ahead. mRNA efforts, such as the Moderna–Korea University collaboration, have shown protective effects in rodent models but require further optimization, GMP manufacturing, and human testing projected into 2028 or later. DNA vaccine candidates against Andes virus completed small Phase 1 studies demonstrating immunogenicity yet need additional dosing regimens and larger trials. The low incidence of hantavirus pulmonary syndrome and geographic dispersion of cases complicate large-scale efficacy testing, while the absence of established surrogate endpoints limits accelerated pathways. A sudden large-scale outbreak could prompt emergency-use considerations, but completing required safety, immunogenicity, and manufacturing milestones within the remaining months of 2026 remains highly improbable.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp